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Abstract 
The hydrophobicity of a drug can be a major challenge in its development and prevents the clinical 
translation of highly potent anti-cancer agents. We have used a lipid-based nanoemulsion termed 
Lipid-Oil-Nanodroplets (LONDs) for the encapsulation and in vivo delivery of the poorly bioavailable 
Combretastatin A4 (CA4). Drug delivery with CA4 LONDs was assessed in a xenograft model of 
colorectal cancer. LC-MS/MS analysis revealed CA4 LONDs, administered at a drug dose four times 
lower than drug control, achieved equivalent concentrations of CA4 intratumorally. We then attached 
CA4 LONDs to microbubbles (MBs) and targeted this construct to VEGFR2. A reduction in tumour 
perfusion was observed in CA4 LONDs-MBs treated tumours.  A combination study with irinotecan 
demonstrated a greater reduction in tumour growth and perfusion (p=0.01) compared to irinotecan 
alone. This study suggests that LONDs either alone or attached to targeted MBs, have the potential 
to significantly enhance tumour-specific hydrophobic drug delivery.   
Keywords 
Lipid-Oil-Nanodroplets (LONDs); Combretastatin A4; Microbubbles; Targeting; Ultrasound trigger 
Introduction 
Poor drug physiochemical properties such as hydrophobicity is one of the main causes of drug failure 
during the early developmental stages. Approximately 40% of currently approved drugs and up to as 
many as 90% of drugs in the discovery pipeline exhibit poor aqueous solubility [1]. As a 
consequence, these compounds suffer from low bioavailability, often with rapid metabolism and 
excretion. The consequent need for higher dosing leads to poor safety and tolerability profiles [1]. 
Among hydrophobic agents with potential value in cancer treatment is the vascular disrupting agent 
(VDA), Combretastatin A4 (CA4). Unlike anti-angiogenic agents which target angiogenesis and 
prevent the development of new blood vessels, VDAs target the already established tumour 
vasculature in the core of the tumour which are often resistant to conventional chemotherapy [2]. 
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flow in the core of the tumour followed by secondary necrosis [3–5]. However, VDAs spare the 
rapidly proliferating cells of the tumour periphery, leaving behind a “viable rim” of cells which is a 
major cause of resistance and the reason for combination treatments with conventional 
chemotherapy [6].  
CA4 is a natural product originally isolated from the African tree Combretum caffum. It is a potent 
inhibitor of microtubule polymerisation [7,8] binding near the colchicine binding site and preventing 
the “curved” to “straight” tubulin transition [9]. In vitro, CA4 causes complete disorganisation of 
cytoskeletal microtubules in endothelial cells, which in vivo manifests as the rapid shutdown of 
tumour vasculature [10,11]. Due to its poor aqueous solubility, the prodrug CA4 phosphate (CA4P) 
has been developed [12]. Although CA4P improves the delivery of CA4, its use in clinical trials was 
compromised by unacceptable off-site toxicities [13,14]. An alternative route to improving solubility of 
hydrophobic compounds such as CA4 is to produce nano-formulations by using liposomes [15], 
polymer based micelles [16] or nanoemulsions [17,18]. 
Nanoparticles show excellent potential as drug-loaded carriers, however, some formulations suffer 
rapid clearance and/or nonspecific accumulation with drug release in healthy tissues [19]. It was 
assumed for many decades that a passive process known as the enhanced permeability and 
retention (EPR) effect was one of the main ways in which nanoparticles entered tumours leading to 
enhanced drug uptake [19]. However, recently, it has been shown using different mouse models, 
different types of human tumours, mathematical modelling and different imaging techniques that 
nanoparticles enter tumours using an active trans-endothelial process, suggesting that targeting of 
tumour endothelial cells may enhance uptake with nanoformulated drugs [20]. 
MBs are intravascular ultrasound (US) contrast agents with diameters in the micrometre range, 
permitting their circulation in the bloodstream. MBs alone can be used in combination with US to 
increase drug-uptake and as drug delivery vehicles by directly incorporating drugs within MBs (within 
the shell) or by attaching payloads to the outside shell [21,22]. Further attachment of a targeting 
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attachment of vascular endothelial growth factor receptor 2 (VEGFR2) antibodies has greatly 
enhanced the MB imaging of tumour vasculature [23]. In vitro and in vivo targeting of MBs to αvβ3 
integrin or intracellular adhesion molecule-1 (ICAM-1) (both upregulated on tumour endothelium) 
have resulted in greater binding, with enhanced drug delivery to tumour endothelium compared to 
non-targeted MBs [24,25]. 
VEGFR2-targeted MBs have been used to enhance delivery of attached liposomal payloads to 
tumours whilst reducing off-site toxicity [22,26]. An external US-trigger can induce localised MB 
oscillation and/or bursting leading to the induction of microstreams, shock waves and microjets [27]. 
These result in the release of the nano-formulated drugs, whilst simultaneously leading to the 
transient opening of pores in neighbouring cell membranes, all potentially contributing to enhanced 
intratumoral drug delivery [18,19].  
We have previously developed lipid-stabilised Oil Nanodroplets (LONDs) for the encapsulation and 
delivery of hydrophobic drugs such as CA4 [28]. LONDs are formed by a two-step high-pressure 
homogenisation process and range between 100-300 nm in diameter. The short chain triglyceride 
tripropionin was used as the oil core, having a water solubility of 0.003 g/L at 37ºC [29]. LONDs are 
stable for over six weeks when stored at 4ºC. Under physiological conditions they exhibit minimal 
changes in size over this period [28]. CA4 was successfully encapsulated in tripropionin LONDs and 
showed cellular uptake and release of CA4 in vitro as evidenced by the disruption of microtubules 
[28].  
In this study, in vivo biodistribution and intratumoral delivery of CA4 with CA4 LONDs and VEGFR2 
targeted CA4 LONDs-MBs (Figure 1) was assessed using a mouse model of human colorectal 
cancer (CRC).  The combined delivery of CA4 LONDs-MBs with the chemotherapeutic agent 
irinotecan was also evaluated in vivo and showed that low doses of CA4 drug delivered in this way 
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Methods 
All experimental details can be found in the Supplementary Material.  
Cell lines   
SW480 cells were used in this study. 
CA4 LOND production and characterisation 
Tripropionin LONDs encapsulating CA4 were produced by a two-step high-pressure homogenisation 
described previously [28].  
CA4 LONDs-MBs microfluidic production and characterisation 
CA4 LOND-MBs were produced in a microfluidic device using a two-step process. The design of the 
microchip had a flow-focusing region for MB production using a microspray regime [30], followed by a 
serpentine to allow for slower mixing of MBs with neutravidin functionalised CA4 LONDs 
(approximately 1.14 s [31]) (Supplementary Figure S1). MB-LONDs were characterised in terms of 
size and concentration. Based on this data, neutravidin VEGFR2 antibody (eBiosciences, UK) was 
added to the MBs at 0.1μg per 107 MBs.  
Mouse models 
Local ethical approval was obtained and all experiments were undertaken in accordance with the UK 
Animals (Scientific Procedures) Act 1986. CD-1® and BALB/c nude mice were bred in-house under 
licence from Charles River Laboratories (Wilmington, MA, USA) and maintained in specific-pathogen-
free conditions in individually ventilated cages with free access to food and water. SW480 cells were 
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Tumour volume measurements  
Tumour xenografts were imaged using a VisualSonics Vevo 770 high-frequency ultrasound system 
(Fujifilm VisualSonics Inc., Ontario, Canada) equipped with 40 MHz (RM-704) and 25 MHz (RM-
710B) transducers as previously described [32,33].  
Determination of vascular perfusion using the perfusion marker Hoechst 
33342 
Tumour perfusion was assessed by uptake of Hoechst 33342, a DNA binding dye that when left in 
the circulation for 1 min, stains the endothelial cells of blood vessels perfused at the time of injection 
[34]. Tumours were also stained with a primary antibody for CD31, visualised using an appropriate 
secondary antibody and imaged using a Zeiss Axioimager Z1 fluorescence microscope with 
AxioVision software (Carl Zeiss Microscopy, USA). Perfusion was scored using a semi-quantitative 
scoring system to define none (score 0), weak (score 1), moderate (score 2) and high (score 3) 
intensity of Hoechst 33342 fluorescent staining by two independent observers blinded to the 
treatment groups. Representative images for the perfusion scoring are shown in Supplementary 
Figure S2 for each data set. Data set 1 was used to score images represented in Figure 4 and data 
set 2 was used to score images represented in Figure 5 of the results section.  
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) for CA4, 
irinotecan, SN38 and SN38G detection  
For the quantification of CA4 loading in LONDs, CA4 LONDs-MBs preparations and tissue samples, 
LC-MS/MS was used. Detection of irinotecan, SN38 and SN38G was performed following the 
method of Ingram et. al. 2020. The MRM setting for irinotecan, SN38 and SN38G are shown in 
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Results  
CA4 LOND characterisation and in vivo biodistribution  
CA4 LONDs were produced and physically characterised prior to in vivo delivery with LC-MS/MS  
being used to quantitate CA4 loading (Table 1). The mean diameter of three preparations of LONDs 
was 93 ± 10 nm as measured by DLS, the diameter was confirmed by particle tracking (NanoSight) 
which also calculated the concentration at 1.6 (± 0.4) ×1014 LONDs/mL. The mean CA4 loading from 
the three preparations was 1.0 ± 0.3 mg/mL measured by LC-MS/MS. The extraction efficiencies and 
limit of detection (LOD) of CA4 for the specifically designed LC-MS/MS method are shown in 
Supplementary Figure S3.  
To assess if drug delivery with CA4 LONDs altered the biodistribution of CA4, mice bearing SW480 
human CRC xenografts were given a single treatment  (preparation 1, Table 1) which equated to a 
dose of 12.8 mg/kg. Free CA4 dissolved in a combination of DMSO/peanut oil at 50 mg/kg (the 
standard dose in preclinical trials [10]) delivered intraperitoneally (i.p.) was used as a control (Figure 
2A and 2B). The concentration of CA4 in tumour, liver and plasma 1 h post treatment was 
determined using LC-MS/MS (Figure 2C). CA4 was only detected in tumours (2/3) from the CA4 
LONDs group, being below the LOD in liver and plasma while in the free CA4 group, CA4 was 
detected in tumours (2/3), in 1/3 liver and 1/3 plasma samples.  
The main metabolite of CA4, CA4 glucuronide (CA4G) was also detected but not quantifiably (due to 
the lack of appropriate standards) in the plasma, liver and tumour from the free CA4 group and liver 
only from the CA4 LONDs group (Supplementary Table S2). The CA4G data suggests that delivery 
of free CA4 leads to its rapid metabolism to CA4G. While the detection of CA4G in the tumour 
samples suggested that CA4 was directly converted to CA4G intratumorally. However, it should be 
noted that due to the intraperitoneal delivery route of free CA4, CA4 may have undergone hepatic 
metabolism before entering the bloodstream. As CA4G was not detected in tumour samples from the 
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for metabolism or encapsulated CA4 is potentially being released slowly into the tumour from the 
LONDs and the levels of CA4G following metabolism are below the LOD. 
Nevertheless, these results confirmed that drug delivery to tumours of CA4 in both free and LOND 
encapsulated forms was possible and also showed that tumours from both groups were exposed to 
similar concentrations of CA4 even though the amount of CA4 in the LONDs was four times lower 
than free CA4.  
Effect of CA4 LONDs on tumour growth following multiple treatments 
As CA4 LONDs successfully delivered CA4 to tumour tissues, the potential of CA4 LONDs to cause 
tumour growth inhibition was assessed. Mice bearing SW480 CRC xenografts received three 
treatments (Tx) of CA4 LONDs (preparation 2, Table 1) or free CA4 dissolved in a combination of 
DMSO/peanut oil or vehicle control DMSO/peanut oil. CA4 LONDs and free CA4 were administered 
at a low dose of 3mg/kg as using higher doses was not sustainable with multiple treatments (Figure 
3A and 3B). CA4 LONDs did not significantly delay the growth of tumours (p=0.8). In contrast, free 
CA4 significantly inhibited tumour growth at day 3 compared to vehicle (p=0.01) and CA4 LONDs 
(p=0.04) (Figure 3C). The % tumour growth inhibition (%TGI) [35] compared to vehicle (% TGI= 1-
(treated final – treated day 0)/ (control final – control day 0)) was 17.5% for CA4 LONDs and 19.3% 
for free CA4. Tumour masses were lower in groups treated with CA4 LONDs and free CA4, while a 
modest increase in tumour doubling time was also observed in groups treated with CA4 LONDs and 
free CA4. However, these did not reach statistical significance when compared to the vehicle 
DMSO/peanut oil (Figure 3D and 3E). 
Tumour response was further assessed by determining the % haemorrhage and necrosis in tumour 
tissue (Figure 3F and 3G). CA4 LONDs and free CA4 did not appear to cause any treatment 
associated haemorrhage as the highest median % haemorrhage was observed in the vehicle group, 
pointing towards inherently leaky tumour vasculature (Figure 3F). Despite extensive necrosis in 1/4 
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vehicle treated tumours (Figure 3G). Treatment with CA4 LONDs and free CA4 did not significantly 
alter the number of CD31+ blood vessels compared to the vehicle (Figure 3H).
Production and evaluation of targeted, ultrasound-triggered CA4 LONDs-
MBs 
Although CA4 LONDs were capable of delivering drug to tumours, the low doses encapsulated and 
delivered failed to significantly inhibit tumour growth. To enhance LOND drug delivery, we 
engineered MBs to carry LONDs. A preliminary study was conducted following the successful 
production of VEGFR2-targeted CA4 LONDs-MBs to assess the delivery of CA4 using the LOND-
MB-construct by detecting changes in tumour perfusion.  
The MB concentration, diameter and CA4 loading of the CA4 LONDs-MBs were 8 × 106/mL, 2.6 ± 1.5 
μm and 0.0001 mg/mL measured by optical imaging and LC-MS/MS, respectively. 0.0001 mg/mL of 
CA4 is the concentration limit for the construct due to the dilutions involved during the two-step 
production process, therefore 0.001 mg/kg was the highest dose that could be delivered. SW480 
CRC xenograft-bearing mice were injected intravenously with CA4 LONDs-MBs at a concentration of 
0.001 mg/kg or CA4P at 50 mg/kg or vehicle (PBS) (Figure 4A and 4B). CA4P was used as the drug 
control to enable the same intravenous delivery route as CA4 LONDs-MBs and at 50 mg/kg to act as 
a positive control as previous studies have shown a reduction in perfusion at concentrations of 50 
mg/kg or above [3,10,36]. A low frequency, high amplitude US pulse was applied at the tumour site 
using a specifically designed custom-built single element US system (UARP) 4 min post-MB 
injection. All groups were exposed to a 5 s US trigger (+T). This was a 10μs tone burst US pulse, 
with a peak negative pressure of 260kPa and 1kHz pulse repetition frequency (PRF), using a 2.2 
MHz transducer designed to destroy the MBs in situ.  
Tumour morphology at 1 h post treatment with CA4 LONDs-MBs or free CA4P was similar to vehicle 
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present to the same extent as the vehicle group. Assessment of perfusion using Hoechst 33342 was 
adopted as a surrogate biomarker of tumour response, since quantitation of tumour necrosis, 
haemorrhage, blood vessel number and tumour volume were not sufficiently sensitive to detect any 
very early tumour responses to CA4 LOND therapy.  
Perfusion in the tumour core was reduced in treated groups compared to vehicle (Figure 4C). 
Perfusion in the tumour periphery was not reduced in the treated groups compared to vehicle (data 
not shown), suggesting that the tumour core was more susceptible to the effects of CA4. Although 
apparent differences in perfusion were observed between the groups, semi-quantitative analysis 
failed to show any statistically significant differences between them (p = 0.1) (Figure 4D). Despite 
this, the fluorescent images showed a marked reduction in perfusion, strongly suggesting the 
successful uptake and/or release of CA4 intratumorally from the CA4 LONDs-MBs construct. 
Combination therapy using low dose irinotecan and US triggered targeted 
CA4 LONDs-MBs 
The results with CA4 LONDs-MBs showed evidence of CA4 uptake/release intratumorally, as a 
reduction in perfusion was observed and this was achieved using a very low dose of CA4 (0.001 
mg/kg). As the delivery of CA4 alone is considered unlikely to be curative [37–39], CA4 LONDs-MBs 
were combined with irinotecan to further enhance the anti-tumour activity achieved with CA4. 
Irinotecan is a prodrug requiring conversion by cellular carboxylesterases to its active metabolite 
SN38, a topoisomerase I inhibitor used in the treatment of CRC and liver metastases [40]. A low and 
frequent dosing schedule (metronomic) was chosen since reports have shown that frequent lower 
doses of CA4P are more effective at sustaining its anti-tumour effects [41]. Irinotecan administered 
using a metronomic schedule has also shown enhanced efficacy, potentially by exerting additional 
anti-angiogenic effects [40,42].
There is conflicting evidence regarding the timing and sequence of administration of CA4P when 
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CA4P is administered after or concurrently with the combination agent, as potential changes to the 
tumour microenvironment induced by CA4P may hinder partner drug uptake [43–46]. Irinotecan (10 
mg/kg) was administered 1 h prior to CA4 LONDs-MBs (0.001 mg/kg) or CA4P (0.001 mg/kg) to treat 
SW480 human CRC xenografts (Figure 5A). CA4 LONDs-MBs and CA4P were administered at the 
same concentration to investigate if the targeted, triggered delivery of CA4 using the LOND-MB 
construct had a greater effect on tumour growth compared to delivering free drug systemically. 
Administrating irinotecan 1 h prior to any other treatment allows for the active metabolite of 
irinotecan, SN38 to reach its peak conversion in the blood [47].  
Mice received five treatments in total over three weeks (Figure 5B). The mean concentration, 
diameter and CA4 loading in CA4 LONDs-MBs used for the five treatments were 3.5 × 107 MBs/mL, 
4 ± 0.3 μm and 0.0001 ± 0.00006 mg/mL respectively (Supplementary Table S3). 
Tumour growth was inhibited in both combination groups with irinotecan and CA4 LONDs-MBs or 
CA4P. Irinotecan + CA4 LONDs-MBs significantly inhibited the growth of tumours by day 11 
compared to vehicle control (PBS) (p = 0.05) (Figure 5C). In contrast the combination therapy with 
irinotecan and CA4P significantly inhibited the growth of tumours from day 7 onwards when 
compared to vehicle (p = 0.01, p = 0.02 and p = 0.04) (Figure 5C). By day 14 after the fourth 
treatment, tumour growth was also inhibited in the irinotecan + CA4P group compared to irinotecan 
alone (p = 0.04) (Figure 5C). The %TGI compared to vehicle was 22.9% for irinotecan only, 88.5% 
for irinotecan and CA4P and 47.8% for irinotecan and CA4 LONDs-MBs. Compared to irinotecan the 
%TGI was 85.1% for irinotecan and CA4P and 32.2% for irinotecan and CA4 LONDs-MBs.  
Tumours in all treatment groups were smaller in mass than vehicle controls. However, only tumours 
in the irinotecan + CA4P group reached statistical significance when compared to vehicle (p = 0.02) 
(Figure 5D). Tumour doubling times were not significantly increased in the irinotecan and CA4P 
group compared to vehicle (Supplementary Figure S4). Tumour regression was also observed in all 
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only very mild body weight loss observed in the irinotecan only group after the initial treatment 
(before recovering by treatment three) (Supplementary Figure S5).  
To determine potential mechanisms by which the combination therapy of irinotecan and CA4 LONDs-
MBs might be enhancing tumour growth inhibition, tumour perfusion was assessed. Tumour sections 
from the vehicle group and the irinotecan only group appeared to be well perfused when compared to 
the combination groups of irinotecan + CA4 LONDs-MBs or CA4P (Figure 5E). Semi-quantitative 
assessment of the fluorescent images demonstrated that tumour perfusion was significantly reduced 
in the irinotecan + CA4 LONDs-MBs combination group compared to vehicle control (p=0.02) (Figure 
5F). No statistical significant difference was observed when comparing irinotecan + CA4 LONDs-MBs 
to irinotecan alone, this was potentially due to irinotecan causing necrosis and a subsequent 
reduction in overall tumour perfusion following the five treatments.   
 
Tumour, tissue drug biodistribution and metabolism following multiple 
treatments  
Tumour and tissue biodistribution of irinotecan and its metabolites were assessed to determine if the 
CA4 LOND MB or free CA4 combinations altered its pharmacokinetic response. The concentrations 
of irinotecan and its active and inactive metabolites, SN38 and SN38G respectively, were determined 
by LC-MS/MS 1 h post final treatment in tumours, plasma, liver, colon (Figure 6) and in spleen, 
kidney, lung and heart tissues (Supplementary Figure S6) 
The presence of CA4 (in the LONDs-MBs construct) or free CA4P did not appear to alter tumour 
metabolism of irinotecan to SN38 and SN38G (Figure 6A). Although, it potentially altered the ability 
of irinotecan to enter the tumour following five treatments as the concentration of irinotecan was 
significantly higher in the irinotecan only group compared to irinotecan + CA4P  (p=0.005) and 
irinotecan  + CA4 LONDs-MBs (p=0.002). This suggested that following five treatments in the 











   
13 
5F hindering the entry of irinotecan. Plasma and liver concentrations of irinotecan, SN38 and SN38G 
(Figure 6B and 6C) were not altered by the combination. Interestingly, the metabolism of irinotecan 
to SN38 and SN38G in colon was much more variable compared to the other organs in all groups  
(Figure 6D) (Supplementary Figure S6).  
 
Discussion  
The issues of drug solubility, limited bioavailability and toxicity have prompted the development of a 
plethora of nano-formulated drugs with various characteristics and potential structural modifications. 
In the present study we have demonstrated that LONDs can be used for the encapsulation and in 
vivo delivery of the hydrophobic drug, CA4. CA4 has been previously incorporated in a number of 
liposomal formulations [48–51]. One potential advantage of our LONDs compared to liposomes is 
that hydrophobic drugs (such as CA4) are encapsulated in the core of the particle rather than 
incorporated in the lipid bilayer of the liposome. Incorporation into the lipid bilayer, although widely 
used for hydrophobic drugs, has several limitations including restrictions in drug loading and the 
potential for drug leakage due to destabilisation of the membrane from changes in the phase 
transition temperature [52].  
The data presented in this study showed that CA4 LONDs administered in vivo at a dose four times 
lower than free CA4, delivered a similar concentration of CA4 intratumorally (~1000 ng/g) with none 
detected (or below the LOD) in the liver or plasma 1 h post treatment. In contrast, CA4 was present 
in the liver and plasma samples from the free CA4 group. It was therefore concluded that CA4 
LONDs were more effective at delivering CA4 to the tumour, without the need for high circulating 
concentrations of free drug. Wang et al., investigated the in vivo tumour and tissue biodistribution of 
CA4/methotrexate co-loaded nanoparticles delivered i.v. at a CA4 dose of 15 mg/kg and found 
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Numerous pre-clinical studies have shown that the effects of a single treatment with CA4 or CA4P on 
the growth of tumours are very limited with modest growth delays only observed at doses higher than 
100 mg/kg. This is mainly attributed to the viable rim remaining post treatment [38]. Therefore in 
order to obtain a better therapeutic response with CA4, multiple dosing regimens are used [41]. The 
timings between treatments in our study were over 24 hours, as a longer retention and prolonged 
exposure in the tumour was anticipated with CA4 LONDs, due to the encapsulation as opposed to 
free drug. However, CA4 LONDs caused a modest but statistically insignificant tumour growth 
inhibition (Figure 3). This was potentially due the timings between treatments as tumours generally 
recover from the effects of CA4 24 and 48 hours post treatment [41,45,54,55]. In contrast, 
administrating free CA4 at 3 mg/kg every other day for a total of five treatments has been shown to 
significantly inhibit growth of hepatocellular carcinoma [53] 
The combination of nanoparticles with targeted MBs and US has been shown to enhance the efficacy 
of drugs by increasing the circulation times and improving drug accumulation in tumour cells [26,27]. 
In this study, CA4 LONDs were attached to VEGFR2-targeted MBs to enable US-triggered delivery. 
Tumour perfusion as assessed by Hoechst 33342 (a perfusion marker) indicated successful delivery 
of CA4 from the LOND-MB construct as a clear reduction in tumour core perfusion was observed, 
with changes to the tumour periphery, consistent with previous reports using CA4P [3,38,56]. A 
greater reduction in perfusion was observed in the free CA4P group (50 mg/kg) compared to CA4 
LONDs-MBs (0.001 mg/kg) most likely due to the large difference in dose. A reduction in perfusion 
has previously been shown to be dose-dependent with CA4 [36] and lack of  tumour response at the 
tumour periphery has been widely reported in animal models [3,4,57]. This has been attributed to the 
differences in vasculature between tumour core and its periphery. Tumour vessels in the periphery 
are more mature, they have a greater investiture of smooth muscle cells and have lower levels of 
hypoxia, as they are close to „normal‟ vessels and have higher expression of VEGF [58].  
To further improve the effectiveness of US-triggered, VEGFR2-targeted CA4 LONDs-MBs these 
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growth inhibition when irinotecan was given with either CA4 LONDs-MBs or CA4P demonstrating that 
longitudinally CA4 LONDs-MBs were as effective at delivering a hydrophobic drug such as CA4 when 
compared to CA4P. The combination of irinotecan and CA4P also significantly inhibited tumour 
growth compared to irinotecan only, indicating some potentiation of the anti-tumour effects of  
irinotecan by CA4P. A number of mechanisms may explain this enhanced activity when the two 
agents are combined. CA4 could induce changes in the tumour microenvironment that enhance the 
cell-killing activity of irinotecan. Our results showed that CA4 LONDs-MBs or CA4P caused a 
reduction in perfusion, potentially leading to the entrapment of irinotecan or its active metabolite 
SN38 in tumour tissue, thus prolonging the exposure times of tumour cells to the active agent. 
Trapping of cytotoxic agents by CA4P and in particular using irinotecan in combination with CA4P, 
has been previously demonstrated [59]. A trapping effect was not observed in the present study as 
the biodistribution data at 1 h post-injection showed the highest concentrations of irinotecan, SN38 
and SN38G in the irinotecan only group. However, these tissues were collected following five 
treatments, therefore the tumour vasculature could potentially have already been significantly altered 
and thus hindered the entry of irinotecan as measured by this final time-point. Single treatments at 
multiple timings of irinotecan and CA4-LONDs-MBs administered would be required to investigate the 
trapping effect.  
The potentiation effect shown with CA4 and irinotecan may also result from their different cell targets 
thus this regimen generates a multi-targeting strategy. Irinotecan acts on the most rapidly 
proliferating tumour cells, whilst in contrast, CA4 affects the established vasculature. This has been 
previously demonstrated with CA4P and 5-fluorouracil (5-FU), where 5-FU inhibited tumour cells in 
the viable rim [44], in this case no trapping was observed. Low dose irinotecan (10 mg/kg x 2 per 
week) has also been shown to suppress the mobilisation of circulating endothelial progenitor cells 
(CEPs) in a murine colon cancer model [60]. CEPs are a known cause of resistance to CA4 [61] 
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Taken together the data presented in this study suggest that LONDs are a promising hydrophobic 
drug delivery nanovehicle. Their use alone or attached to MBs suggests that this technology has the 
potential to enhance drug delivery of poorly water-soluble drugs while significantly reducing the need 
for high circulating concentrations. Furthermore, the combination of low dose irinotecan and CA4 
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Figure legends 
Figure 1. CA4 LONDs-MB schematic. The CA4 LONDs-MB construct consists of a lipid/PEG 
coated MB (light green representing the gas C4F10 core with red shell) covalently conjugated (through 
biotin/neutravidin interactions) to a layer of LONDs (yellow with purple shell) encapsulating CA4 
(dissolved in oil). The construct also carries anti-VEGFR2 antibodies to promote tumour specific 
delivery by allowing accumulation in tumour vasculature where VEGFR2 is more prevalent than in 
normal vasculature. 
Figure 2. In vivo biodistribution of CA4 1 h post treatment with CA4 LONDs. (A) Treatment 
groups, doses used and delivery route are shown in brackets (n = number of mice per group). (B) 
Schematic of the treatment (Tx) schedule. Day 0 is the pre-treatment day where the mean (± SD) 
starting tumour volumes and mouse weights for each group were 53 (± 63) mm3 and 33 (± 4) g for 
CA4 LONDs and 64 (± 22) mm3 and 33 (± 4) g for free CA4. (C) CA4 concentrations in tumour, liver 
and plasma tissue 1 h post treatment with CA4 LONDs (12.8 mg/kg) and free CA4 (50 mg/kg). Limit 
of detection (LOD) for CA4 was 10ng/mL.  
Figure 3. Tumour pharmacodynamic response to CA4 LONDs. (A) Treatment groups, doses and 
delivery route used are shown in brackets (n = number of mice per group). (B) Schematic of the 
treatment (Tx) schedule and 3D high frequency ultrasound (HFUS) imaging. Day 0 is the pre-
treatment day where the mean (± SD) starting tumour volumes and mouse weights for each group 
were 147 (± 89) mm3 and 21 (± 1) g for CA4 LONDs, 178 (± 89) mm3 and 20 (± 1) g for free CA4 and 
157 (± 129) mm3 and 21 (± 3) g for vehicle which was not statistically significantly different at this 
time point. (C) Tumour volumes were measured by HFUS and the ratio to day 0 pre-treatment was 
plotted. Tumour growth rate was significantly inhibited at day 3 in the free CA4 group compared to 
vehicle (p=0.01) and CA4 LONDs (p=0.04). Mann-Whitey U-test, two-tailed. Data represents the 
mean ± SEM. (D) Tumour mass in grams, * calculated mass based on the HFUS measurements at 
day 10 due to not measuring the weight at the time. (E) Tumour doubling time (days), was derived by 











   
26 
mm2 of tumour. (G) % necrosis per mm2 of tumour. (H) Number of vessels per mm2 of tumour were 
also manually counted. Horizontal lines (⎯) represent the median in D-H. 
Figure 4. CA4 LONDs-MBs in vivo evaluation of tumour delivery and vascular shutdown 
following a single treatment. (A) Treatment groups, doses used and the number of mice per group 
(n). All groups were exposed to an US trigger (+T). (B) Schematic of the treatment (Tx) schedule and 
3D high frequency ultrasound (HF-US) imaging. Day 0 is the pre-treatment day where the mean (± 
SD) starting tumour volumes for each group were 248 (± 79) mm3 for CA4 LONDs-MBs, 273 (± 147) 
mm3 for CA4P and 224 (± 242) mm3 for vehicle, these were not statistically significantly different at 
this time point.  (C) Representative fluorescent images of tumour sections showing perfusion in the 
tumour core stained with Hoechst 33342 in situ (blue) and CD31 vessels stained ex vivo (red). Scale 
bars indicate 50μm. (D) Hoechst 33342 intensity scoring used to score perfusion (see Supplementary 
Figure S2 for scoring index). The data represents the median and error bars the interquartile range. 
Significance was calculated using a Mann-Whitney U test, two-tailed. A.U. arbitrary units. Horizontal 
line (⎯) represents the median value.  
Figure 5. Combination therapy using irinotecan and CA4 LONDs-MBs to treat CRC. (A) 
Treatment groups, doses used and delivery route (n= number of mice per group). All groups were 
exposed to an US trigger (+T). (B) Treatment schedule. Mice received five treatments (Tx) in total 
over three weeks. 1 h after the fifth and final treatment tumours were excised for ex vivo analysis. 
Day 0 is the pre-treatment day where the mean (± SD) starting tumour volumes for each group were 
99 (± 46) mm3 for irinotecan + CA4 LONDs-MBs, 95 (± 70) mm3 for irinotecan + CA4P, 91 (± 46) 
mm3 for irinotecan only and 97 (± 26) mm3 for vehicle, these were not statistically significantly 
different at this time point. (C) Tumour growth rate is plotted. Data represents the mean ± SEM, p 
values were determined by Mann-Whitney U test, two tailed. *1 p=0.01 (irinotecan + CA4P vs 
vehicle), *2 p=0.02 (irinotecan + CA4P vs vehicle), *3 p=0.05 (irinotecan + CA4 LONDs-MBs vs 
vehicle), *4 p=0.04 (irinotecan + CA4P vs vehicle), *5 p=0.04 (irinotecan + CA4P vs irinotecan). (D) 
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group compared to PBS (p=0.02). Horizontal line (⎯) represent the median. (E) Representative 
fluorescent images of tumour sections showing tumour perfusion in the tumour core stained with 
Hoechst 33342 in situ (blue) and CD31 vessels (red) stained ex vivo. Scale bars indicate 50μm. (F) 
Hoechst 33342 intensity scoring used to score perfusion. A statistical significant difference (p=0.02) 
was observed between vehicle and irinotecan + CA4 LONDs-MBs. The data represents the median 
score from two independent blinded assessors and the error bars denote the interquartile range. 
Significance was calculated using a Mann-Whitey U test, two-tailed. 
Figure 6. Tumour and tissue biodistribution of CA4, irinotecan and its active and inactive 
metabolites SN38 and SN38G 1 h post-treatment. For treatment groups and dosing schedule, see 
Figure 5A and 5B. The concentrations of irinotecan, SN38 and SN38G per gram of tissue were 
determined in (A) tumour, (B) plasma, (C) liver and (D) colon. Two-way ANOVA followed by Holm-
Sidak‟s multiple comparisons test showed a significantly higher concentration of irinotecan was 
observed in the irinotecan only group compared to irinotecan + CA4P (p=0.005) and irinotecan + 
CA4 LONDs-MBs (p=0.002). Horizontal line (⎯) represents the median value. LOD for irinotecan, 
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Table 1: LOND characterisation: The mean diameter of LONDs and concentration was measured 
by DLS and NanoSight respectively. The mean and standard deviation (SD) were calculated. CA4 










1 1.2 89  1.3 
2 1.7 87  0.7 
3 2 104 0.9 
Mean 1.6 93 1 
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List of Abbreviations 
5-FU 5-fluorouracil 
CA4 Combretastatin A4 
CA4G CA4 glucuronide  
CA4P CA4 phosphate 
CEPs Circulating endothelial progenitor cells 
CRC Colorectal cancer 
EPR Enhanced permeability and retention  
i.p.  Intraperitoneal  
i.v. Intravenous  
ICAM-1 Intracellular adhesion molecule-1 
LOD Limit of detection 
LONDs Lipid-Oil-Nanodroplets 
MBs Microbubbles 
TGI Tumour growth inhibition 
Tx Treatment 
US Ultrasound 
VDA Vascular disrupting agent 
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Graphical Abstract: short description  
A number of highly potent and promising drugs fail to reach the clinic due to poor-water solubility. 
Lipid-stabilised Oil Nanodroplets (LONDs) were produced specifically for the encapsulation of poorly-
water soluble drugs such as the vascular disruptive agent Combretastatin A4 (CA4). Initial pre-clinical 
work with CA4 LONDs showed an accumulation of CA4 in tumour tissue. Attachment of CA4 LONDs 
to VEGFR2-targeted Microbubbles (MBs) permitted the controlled and ultrasound triggered, release 
of CA4 in tumours, confirmed by a reduction in tumour perfusion post-treatment. The combination of 
low dose irinotecan with CA4 LONDs-MBs further enhanced the anti-tumour effects of both 
compounds.    
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